VCEL
Vericel Corp
NASDAQ · Healthcare · Biotechnology · US
$40.02
−0.02%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$39.55
From 52W high−17.16%
Volume1.12M
Market cap$2.05B
P/E (TTM)83.4x
P/S (TTM)6.7x
Div yield—
Key dataSep 18, 2026
Open
$39.55
From 52W high
−17.16%
Volume
1.12M
Market cap
$2.05B
ValuationView details →
P/E (Fwd)
57.0x
EV/EBITDA
51.5x
P/E (TTM)
83.4x
RSI (14)
41.5
MomentumView details →
1D Return
−0.02%
YTD Return
+10.31%
SummaryUpdated Jun 1, 2026
Vericel Corporation (NASDAQ:VCEL) is a commercial-stage biopharmaceutical company founded in 1989 and headquartered in Cambridge, Massachusetts. Originally incorporated as Aastrom Biosciences, the company went public in 1997 and later rebranded to Vericel Corporation. The company specializes in developing, manufacturing, and commercializing autologous cellular therapies, which are treatments that use a patient's own cells to repair damaged tissue. Vericel has successfully transitioned from a research-focused organization to a profitable commercial enterprise, with two FDA-approved products generating revenue in specialized medical markets.
Similar companies
Latest newsMore news →
Bank of America Corp DE increased its stake in Vericel Corporation by 19.7% during the quarter, acquiring an additional 180,761 shares, according to its SEC disclosure.36d agoVericel Corporation's Board of Directors authorized a $200 million share repurchase program.52d agoVericel Corporation reported financial results for the second quarter ended June 30, 2026, with total net revenue of $77.5 million, net income of $2.2 million, and free cash flow of $14.3 million.52d ago